Scalper1 News
Big pharma Merck (MRK) reported Wednesday that its recently approved melanoma drug Keytruda showed promise in a small, early study of patients with a particularly hard-to-treat form of breast cancer. The study gave Keytruda, the first of a new class of drugs called PD-1 inhibitors, to 27 patients with advanced triple-negative breast cancer. Triple-negative means the cancer is not driven by estrogen, progesterone or the HER2 protein, so it doesn’t Scalper1 News
Scalper1 News